Author Archives: admin


NKY community helping raise money for mother and teacher in need of lifesaving surgery – WKRC TV Cincinnati

NKY community helping raise money for mother and teacher in need of lifesaving surgery

NKY community helping raise money for mother and teacher in need of lifesaving surgery (Lindsey Hughes)

FORT MITCHELL, Ky. (WKRC) - A Northern Kentucky mother and teacher needs help covering the cost of a highly-expensive, but lifesaving medical procedure.

NKY community helping raise money for mother and teacher in need of lifesaving surgery (WKRC, Lindsey Hughes)

A fundraiser was held Sunday afternoon at The Braxton Barrel House for Lindsey Hughes. She's battlingsystemic scleroderma, a rare autoimmune disease.

Hughes is a teacher at Beechwood High School, and a new mother.

NKY community helping raise money for mother and teacher in need of lifesaving surgery (Lindsey Hughes)

In October 2022, after years of suffering, doctors diagnosed her with the disease. It affects her skin and internal organs.

"I went up to the University of Michigan. There's a scleroderma center and the doctors there told me if I want to be able to see my daughter grow up and live a functional life again, I need a stem cell transplant, said Hughes.

Hughes says both the University of Michigan and the Mayo Clinic have approved her for the transplant. She's currently going through pre-transplant testing.

NKY community helping raise money for mother and teacher in need of lifesaving surgery (Lindsey Hughes)

With the price of the procedure starting at $250,000, it's unclear what, if any, help insurance will be.

Thanks to donations and fundraisers, Hughes is getting closer to covering the cost that she hopes will give her future quality time with her family and friends.

"I feel great today. Physically, Im exhausted, but its been so amazing to see friends and family come out to give support, she said.

For more information about Hughes and how you can help, check out the Facebook page about her journey and her GoFundMe campaign.

See the original post:
NKY community helping raise money for mother and teacher in need of lifesaving surgery - WKRC TV Cincinnati

New Insights on Treating Neurodegeneretive Diseases Could Lead … – MarketScale

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimers in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimers disease medications are giving new options to patients.

Alzheimers research is getting to a place where cancer research was maybe 30, 40 years ago, says Anton Porsteinsson, MD, director of the Alzheimers Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. I think were at a point where were going to see a logarithmic increase in discovery.

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dungs Thoughts

Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimers disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinsons disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best weve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently.

Article written by Sonya Young.

Continued here:
New Insights on Treating Neurodegeneretive Diseases Could Lead ... - MarketScale

Hospital Acquired Disease Testing Market, Size is estimated to be US$ 14.91 billion by 2030 with a CAGR of – EIN News

Hospital Acquired Disease Testing Market - PMI

The report "Hospital Acquired Disease Testing Market, By Test Type - Trends, Analysis and Forecast till 2029.

Key Highlights:

In December 2021, the healthians and QRX launch rapid PCR covid test with turnaround time of 30 minutes.

Analyst View:

The rise of hospital acquired diseases is fueled by poor infection control techniques and procedures at healthcare facilities, as well as filthy and non-sterile environmental surfaces, which is propelling the hospital acquired disease testing market forward. Furthermore, rising antibiotic resistance as a result of enhanced medical treatment leads to the development of hospital-acquired infections, which fuels market expansion. Furthermore, the market is being driven by the rising occurrence of nosocomial infections such as surgical wounds, urinary tract infections, and lower respiratory tract infections in intensive care units, orthopedics, and acute surgical wards.

Improper infection control practices and procedures at healthcare center Improper infection control practices and procedures at healthcare center and unclean and non-sterile environmental surfaces lead to development of hospital acquired diseases, which is driving growth of the hospital acquired disease testing market. Furthermore, increasing antibiotic resistance due to adoption of advanced medical care results into development of hospital acquired diseases, which in turn is fueling growth of the market. Moreover, increasing prevalence of nosocomial infections such as surgical wounds, urinary tract infections, and lower respiratory tract infections in intensive care units, orthopedic, and acute surgical ward are driving growth of the market. Hospital acquired infection is a major burden for society, patients, and healthcare management. Increasing awareness among population regarding hospital acquired infections, adoption of infection control programs by healthcare facilities, maintaining personal hygiene by the hospital staff, complete sterilization of medical equipment, and a clean sanitary environment in the health care facilities may restrain growth of the hospital acquired disease testing market.

Get a Sample Copy of the Hospital Acquired Disease Testing Market: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/98

Key Market Insights from the report:

Hospital Acquired Disease Testing Market accounted for US$ 7.2 billion in 2020 and is estimated to be US$ 14.91 billion by 2030 and is anticipated to register a CAGR of 7.6%. Global Hospital Acquired Disease testing market is segmented into test type and region. Based on Test Type, the Global Hospital Acquired Disease Testing Market is segmented into Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others. By Region, the Global Hospital Acquired Disease Testing Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Hospital Acquired Disease Testing Market:

The key players in the global Hospital Acquired Disease Testing market includes; Diatherix laboratories Life technologies Cantel Medical Corporation Meridian Biosciences Qiagen GmbH Nordion Roche Cepheid

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Some Important Points Answered in this Market Report Are Given Below: Explains an overview of the product portfolio, including product development, planning, and positioning Explains details about key operational strategies with a focus on R&D strategies, corporate structure, localization strategies, production capabilities, and financial performance of various companies. Detailed analysis of the market revenue over the forecasted period. Examining various outlooks of the market with the help of Porters five forces analysis, PEST & SWOT Analysis. Study on the segments that are anticipated to dominate the market. Study on the regional analysis that is expected to register the highest growth over the forecast period

Get Free PDF Download of Hospital Acquired Disease Testing Market: https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/98

Market Segmentation:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Hospital Acquired Disease Testing Market report based on Test Type and Region.

By Test Type - Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others

Regional Insights:

On the basis of region, the global plant stem cells market finds its scope in North America, Europe, Latin America, Asia Pacific, Middle East and Africa. India hospital acquired infection diagnostics market is predicted to rise significantly due to rising occurrence of nosocomial illnesses such as surgical site infections and bloodstream infections. After completing a study on 10,835 patients in diverse clinical settings, India observed a 4.4 percent overall growth rate for hospital acquired illnesses, according to the Indian Journal of Basic and Applied Medical Research.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Topics Related:

Oncology Molecular Diagnostics Market, By Product (Reagents, Instruments, and Others), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, and Others), By Technology (In-Situ Hybridization, Polymerase Chain Reaction (PCR), Next Generation Sequencing, Spectrometry, Transcription Mediated Amplification, and Others), By End-Users (Diagnostic Centers, Hospitals, Academic & Research Institutes, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Influenza Diagnostics Market, By Type (RT-PCR, Viral Culture, Antigen Detection Tests, Serological Assays, Simple Amplification-based Assays, Molecular Assays, and Others) By End-Users (Hospitals, Clinics, Diagnostic Laboratories and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Shweta RaskarProphecy Market Insights+1 860-531-2701email us hereVisit us on social media:FacebookTwitterLinkedIn

Read this article:
Hospital Acquired Disease Testing Market, Size is estimated to be US$ 14.91 billion by 2030 with a CAGR of - EIN News

Hearing loss research: 5 advancements in the past year – Labiotech.eu

At present, more than 1.4 billion people live with hearing loss globally. Hearing disorders are often caused by aging, frequent exposure to loud noises and even hereditary factors. In this article, we will look at some of the latest advancements in hearing disorders research which could broaden the scope for treatments and other measures to curb auditory loss.

Hearing loss research was first documented in 1550 BC in an Ancient Egyptian medical text Ebers Papyrus, which contained a remedy for Ear that Hears Badly; an outlandish concoction of liquids like olive oil, red lead, goat urine and ant eggs, to be injected into the ear.

Then, in the 16th century, the first school to teach sign language to pupils who were deaf, was established in Spain. And, in a major breakthrough in scientific research, the first-ever pair of hearing aids, ear trumpets were developed in the 1610s, which resembled a horn.

In 1898, the first portable hearing aid which used a carbon transmitter to convert weak signals to strong ones, was developed by American electrical engineer Miller Rees Hutchinson.

However, the mass production of hearing aids only began in the early 1900s, with the devices getting more compact and convenient to use as technology progressed. Soon enough, the invention of the cochlear implant (CI) transformed therapeutic research when the first one was successfully implanted by two doctors in California, in the U.S..

Currently, there are various studies being conducted to determine how the factors contributing to hearing loss could be altered to potentially cure hearing disorders. Here are five of the latest studies on hearing disorders, which could possibly influence therapeutic research in the field.

A new research has revealed a link between hearing loss and dementia in older adults.

The research, which was published by Johns Hopkins Bloomberg School of Public Health in Maryland, U.S.A in January 2023, showed that people, specifically older adults who have been diagnosed with hearing disorders, are more likely to have dementia a condition that is associated with the decline in brain functioning where symptoms affect memory, attention and other mental abilities.

However, the greater discovery is that the likelihood of dementia was lower among those who wore hearing aids.

This study refines what weve observed about the link between hearing loss and dementia, and builds support for public health action to improve hearing care access, said Alison Huang, who is the lead author of the research paper and a senior research associate in the Bloomberg Schools Department of Epidemiology and at the Cochlear Center for Hearing and Public Health.

The medical trials studied 2,413 individuals, nearly 50% of them being over the age of 80, where the prevalence of dementia was 61% higher among those participants with moderate to severe hearing loss when compared to participants who had normal hearing. Moreover, the use of hearing aids exhibited a decrease in the prevalence of dementia by 32% in 853 participants who had moderate and severe hearing loss, indicating that treating hearing disorders could lower the risk of dementia.

The research is part of a larger investigative analysis National Health and Aging Trends Study (NHATS) which began in 2011, and is funded by the National Institute on Aging in the U.S..

Although the reason why people with hearing loss have a greater possibility of being diagnosed with dementia is yet to be determined through further clinical studies which will take place this year this breakthrough drives the need for more hearing loss therapies.

A step forward in hearing disorders research, studies have shown that there could be a potential for the reversal of hearing loss.

The research, which was conducted by Del Monte Institute for Neuroscience at the University of Rochester in New York, in the U.S., has found that although cochlear hair cells (sensory cells for hearing) cannot be repaired in human beings with hearing loss, the cells can be regenerated in birds and fish, influencing research in cell regeneration in mammals.

Previously, it was discovered that the expression of ERBB2 an active growth gene was able to activate the development of new hair cells in mammals, but the mechanism behind it was not fully understood initially, according to Patricia White, a professor of Neuroscience and Otolaryngology at the University of Rochester Medical Center. Eventually, it was found that the activation of ERBB2 triggered a cascade of cellular events where the cells began to multiply to become new sensory hair cells.

The study, published in January 2023, examined the process of regeneration of hair cells in mice using single-cell RNA sequencing, where the overactive ERBB2 was observed. It was determined that this signaling promoted stem cell-like development with the expression of proteins through the CD44 receptor which are present in the hair cells.

This discovery has made it clear that regeneration is not only restricted to the early stages of development. We believe we can use these findings to drive regeneration in adults, said Dorota Piekna-Przybylska, scientist and an author of the study.

Data from 3.5 million Danes were gathered to determine a link between traffic noise and the risk of tinnitus a condition which causes a ringing in the ears.

The study was conducted by the University of Southern Denmark (SDU) and published in Environmental Health Perspectives in February 2023, to recognize whether varying degrees of noise can result in being diagnosed with tinnitus. The research established that with an increase in every ten decibels, the risk of developing tinnitus increases by six percent, according to Manuella Lech Cantuaria, researcher and assistant professor at the Maersk Mc-Kinney-Moller Institute at SDU.

This followed a study in 2021 that found a correlation between traffic noise and dementia, particularly Alzheimers disease.

These findings contribute to the growing evidence of sounds of traffic being a detrimental pollutant affecting health, particularly of city-dwellers in congested areas.

We want to increase the focus on the health risks associated with being exposed to noise, which is not only an annoyance but also harmful to your health. Hopefully, our results can help influence urban development, said Cantuaria, who believes that noise regulation programs such as highway shielding and noise-reducing asphalt should be considered.

The efficacy of cochlear implants could be improved, according to a new study that targets the locus coeruleus a region in the brainstem that produces the hormone noradrenaline which is a neurotransmitter.

The study used rat models that were fitted with cochlear implants to determine the performance of the devices. It was observed that the stimulation of the locus coeruleus through its production of noradrenaline led to improved effectiveness of the implants.

Researchers monitored two groups of rats one set with a stimulated locus coeruleus and the other without, after training them to respond to auditory stimuli. The ones which had an activated brainstem learned faster and responded to the tasks quicker. These rats completed the auditory task within three days while those that did not receive the boost took up to 16 days, indicating the role of the locus coeruleus in reviving hearing.

Researchers of the study have pointed out the relevance of the locus coeruleus in mirroring the rat models ability and have stated the need for noninvasive mechanisms to trigger regions of the brain for further studies for hearing disorders.

Aminoglycosides, a class of antibiotics which are used as prophylactics treatments to prevent diseases and to treat infections in the urinary tract and abdomen, have been found to cause the dysfunction of autophagy the recycling of old cells in hair cells, leading to permanent hearing loss.

These findings have given rise to the research potential for therapeutic autophagy components to target aminoglycosides ototoxicity (drug-induced hearing loss), according to the research which was conducted by Indiana University School of Medicine in the U.S..

According to Bo Zhao, researcher and assistant professor at the Indiana University School of Medicine, the translocation of RIPOR2 a protein required for auditory perception caused by the binding of the aminoglycosides to the protein, affects autophagy activation, resulting in hair cell death.

The scientists found that reducing the expression of RIPOR2 prevented the death of hair cells in mice.

The proteins which were identified in the research could be significant drug targets for hearing loss which is caused by medicines like antibiotics.

New technologies related to hearing loss:

Link:
Hearing loss research: 5 advancements in the past year - Labiotech.eu

MAGENTA THERAPEUTICS, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com

The following discussion and analysis of our financial condition and results ofoperations should be read in conjunction with our consolidated financialstatements and related notes appearing at the end of this Annual Report on Form10-K. Some of the information contained in this discussion and analysis or setforth elsewhere in this Annual Report on Form 10-K, including information withrespect to our plans and strategy for our business, includes forward-lookingstatements that involve risks and uncertainties. As a result of many factors,including those factors set forth in the "Risk Factors" section of this AnnualReport on Form 10-K, our actual results could differ materially from the resultsdescribed in, or implied by, the forward-looking statements contained in thefollowing discussion and analysis.

Overview

Magenta Therapeutics, Inc. is a biotechnology company focused on improving stemcell transplantation.

In February 2023, after a review of Magenta's programs, resources andcapabilities, including anticipated costs and timelines, we announced thedecision to halt further development of our programs. Specifically, wediscontinued the MGTA-117 Phase 1/2 clinical trial in patients withrelapsed/refractory acute myeloid leukemia, or R/R AML, and myelodysplasticsyndromes, or MDS. We discontinued the MGTA-145 Phase 2 stem cell mobilizationclinical trial in patients with sickle cell disease, or SCD. Lastly, we stoppedincurring certain costs relating to MGTA-45, including manufacturing and costsrelating to certain other activities that were intended to support aninvestigative new drug application, or IND, for MGTA-45 (previously namedCD45-ADC). As a result of these decisions, we conducted a corporaterestructuring that resulted in a reduction in our workforce by 84%.

Coinciding with the decisions related to the programs and across the portfolio,we announced that we intended to conduct a comprehensive review of strategicalternatives for the company and its assets. As part of our strategic reviewprocess, we are exploring potential strategic alternatives that include, withoutlimitation, an acquisition, merger, business combination or other transaction.We are also exploring strategic transactions regarding our product candidatesand related assets, including, without limitation, licensing transactions andasset sales. There can be no assurance that the strategic review process or anytransaction relating to a specific asset, will result in Magenta pursuing such atransaction(s), or that any transaction(s), if pursued, will be completed onterms favorable to Magenta and its stockholders in the existing Magenta entityor any possible entity that results from a combination of entities. If thestrategic review process is unsuccessful, our board of directors may decide topursue a dissolution and liquidation of Magenta.

Our product candidates have been designed to improve the patient experience whenpreparing for stem cell transplant or gene therapy. Our MGTA-117 productcandidate was designed as an antibody drug conjugate, or ADC, designed todeplete CD117-expressing stem cells in the bone marrow in order to make room forsubsequently transplanted stem cells or ex vivo gene therapy products. Theprocess of making room in the bone marrow is known as conditioning, and thecurrent standard of care for conditioning utilizes chemotoxic agents. Our secondtargeted conditioning product candidate, MGTA-45, is an ADC designed toselectively target and deplete both stem cells and immune cells, and it isintended to replace the use of chemotherapy-based conditioning prior to stemcell transplant in patients with blood cancers and autoimmune diseases. Lastly,our MGTA-145 product candidate, in combination with plerixafor, is designed toimprove the stem cell mobilization process by which stem cells are mobilized outof the bone marrow and into the bloodstream to facilitate their collection forsubsequent transplant back into the body for the purpose of resetting the immunesystem.

In January 2023, we voluntarily paused dosing in our MGTA-117 Phase 1/2 clinicaltrial for MGTA-117 in patients with R/R AML and MDS after the last participantdosed in Cohort 3 in the clinical trial experienced a Grade 5 serious adverseevent, or SAE (respiratory failure and cardiac arrest resulting in death) deemedto be possibly related to MGTA-117. This safety event was reported to the FDA asthe study's third safety event which is of a type referred to as a "Suspected,Unexpected, Serious Adverse Reaction," or SUSAR. The FDA subsequently placed thestudy on partial clinical hold in February 2023.

In April 2022, we announced a plan to more narrowly focus our capital allocationon the MGTA-117 targeted conditioning program, the MGTA-45 IND-enablingactivities and the MGTA-145 stem cell mobilization efforts in sickle celldisease while also de-prioritizing other portfolio investments. We made certainreductions in our planned spending related to research platform-relatedinvestments in new disease targets, paused certain MGTA-145 investments,including the program's planned MGTA-145 dosing and administration optimizationclinical trial in healthy subjects and reduced planned general andadministrative expenses. In connection with these reductions to our plannedspending, we also reduced our workforce by 14%.

Since our inception in 2015, we have focused substantially all of our effortsand financial resources on organizing and staffing our company, businessplanning, raising capital, acquiring and developing our technology, identifyingpotential product candidates

--------------------------------------------------------------------------------

Table of Contents

and undertaking preclinical studies and clinical trials, including MGTA-117,MGTA-45 and MGTA-145. We do not have any products approved for sale and have notgenerated any revenue from product sales.

Since our inception, we have incurred significant operating losses. Net losseswere $76.5 million and $71.1 million for the years ended December 31, 2022 and2021, respectively. As of December 31, 2022, we had an accumulated deficit of$402.0 million.

We expect to continue to incur costs and expenditures in connection with theprocess of evaluating our strategic alternatives. There can be no assurance,however, that we will be able to successfully consummate any particularstrategic transaction. The process of continuing to evaluate these strategicoptions may be very costly, time-consuming and complex and we have incurred, andmay in the future incur, significant costs related to this continued evaluation,such as legal, accounting and advisory fees and expenses and other relatedcharges. A considerable portion of these costs will be incurred regardless ofwhether any such course of action is implemented or transaction is completed.Any such expenses will decrease the remaining cash available for use in ourbusiness. In addition, any strategic business combination or other transactionsthat we may consummate in the future could have a variety of negativeconsequences and we may implement a course of action or consummate a transactionthat yields unexpected results that adversely affects our business and decreasesthe remaining cash available for use in our business or the execution of ourstrategic plan. There can be no assurances that any particular course of action,business arrangement or transaction, or series of transactions, will be pursued,successfully consummated, lead to increased stockholder value, or achieve theanticipated results. Any failure of such potential transaction to achieve theanticipated results could significantly impair our ability to enter into anyfuture strategic transactions and may significantly diminish or delay any futuredistributions to our stockholders.

Should we resume development of our product candidates, our ability to generateproduct revenue sufficient to achieve profitability will depend heavily on thesuccessful development and eventual commercialization of one or more of ourproduct candidates. In addition, we will incur substantial research anddevelopments costs and other expenditures to develop such product candidatesparticularly as we:

enroll and conduct clinical trials for our product candidates;

initiate and conduct preclinical studies and clinical trials of our otherproduct candidates;

develop any other future product candidates we may choose to pursue;

seek marketing approval for any of our product candidates that successfullycomplete clinical development, if any;

maintain compliance with applicable regulatory requirements;

develop and scale up our capabilities to support our ongoing preclinicalactivities and clinical trials for our product candidates and commercializationof any of our product candidates for which we obtain marketing approval, if any;

maintain, expand, protect and enforce our intellectual property portfolio;

develop and expand our sales, marketing and distribution capabilities for ourproduct candidates for which we obtain marketing approval, if any; and

expand our operational, financial and management systems and increase personnel,including to support our clinical development and commercialization efforts andour operations as a public company.

If we resume development of our product candidates, we will not generate revenuefrom product sales unless and until we successfully complete clinicaldevelopment and obtain regulatory approval for our product candidates. If weobtain regulatory approval for any of our product candidates, we expect to incursignificant expenses related to developing our commercialization capability tosupport product sales, marketing and distribution. Further, we expect to incuradditional costs associated with operating as a public company.

Should we resume development of our product candidates, we will need substantialadditional funding to support our continuing operations. Until such time as wecan generate significant revenue from product sales, if ever, we expect tofinance our operations through a combination of equity offerings, debtfinancings, collaborations, strategic alliances and marketing and distributionor licensing arrangements. We may be unable to raise additional funds or enterinto such other agreements or arrangements when needed on favorable terms, or atall. Additionally, because of the numerous risks and uncertainties associatedwith pharmaceutical product development, we are unable to accurately predict thetiming or amount of increased expenses or when or if we will be able to achieveor maintain profitability. Even if we are able to generate product sales, we maynot become profitable. Accordingly, if we fail to raise capital or enter intonecessary strategic agreements, or fail to ever become profitable, we may haveto significantly delay, scale back or discontinue the development andcommercialization of one or more of our product candidates, and we may also beforced to reduce or terminate our operations.

--------------------------------------------------------------------------------

Table of Contents

As of December 31, 2022, we had cash, cash equivalents and marketable securitiesof $112.0 million. Based on our current operating plan, we believe that ourexisting cash, cash equivalents and marketable securities will enable us to fundour operating expenses and capital expenditure requirements for the next twelvemonths from the issuance date of this Annual Report on Form 10-K. See "Item 2.Management's Discussion and Analysis of Financial Condition and Results ofOperations - Liquidity and Capital Resources."

Impact of the COVID-19 Pandemic

The COVID-19 pandemic, including the emergence of various variants, has causedand could continue to cause significant disruptions to the U.S., regional andglobal economies and has contributed to significant volatility and negativepressure in financial markets.

We have been carefully monitoring the COVID-19 pandemic and its potential impacton our business and have taken important steps to help ensure the safety of ouremployees and their families and to reduce the spread of COVID-19 in theCambridge community. We have established a hybrid work-from-home policy for allemployees, as well as safety measures for those using our offices and laboratoryfacilities that are designed to comply with applicable federal, state and localguidelines instituted in response to the COVID-19 pandemic. We will continue toassess those measures as COVID-19-related guidelines evolve.

The future impact of the COVID-19 pandemic on our industry, the healthcaresystem and our current and future operations and financial condition will dependon future developments, which are uncertain and cannot be predicted withconfidence. These developments may include, without limitation, changes in thescope, severity and duration of the pandemic, the actions taken to contain thepandemic or mitigate its impact, including the adoption, administration andeffectiveness of available vaccines, the effect of any relaxation of currentrestrictions within the Cambridge community or regions in which our partners arelocated and the direct and indirect economic effects of the pandemic andcontainment measures. See "Item 1A. Risk Factors" for a discussion of thepotential adverse impact of COVID-19 on our business, results of operations andfinancial condition.

Components of Our Results of Operations

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for ourresearch activities, including our drug discovery efforts, and the developmentof our product candidates, which include:

employee-related expenses, including salaries and related costs, and stock-basedcompensation expense, for employees engaged in research and developmentfunctions;

expenses incurred in connection with the preclinical and clinical development ofour product candidates, including under agreements with contract researchorganizations, or CROs;

the cost of consultants and third-party contract development and manufacturingorganizations, or CDMOs, that manufacture drug products for use in ourpreclinical studies and clinical trials;

facilities, depreciation and other expenses, which include direct and allocatedexpenses for rent and maintenance of facilities, insurance and supplies; and

payments made under third-party licensing agreements.

We expense research and development costs to operations as incurred. Advancepayments for goods or services to be received in the future for use in researchand development activities are recorded as prepaid expenses. The prepaid amountsare expensed as the related goods are delivered or the services are performed.

Our direct research and development expenses are tracked on a program-by-programbasis and consist primarily of external costs, such as fees paid to consultants,central laboratories, contractors, CDMOs and CROs in connection with ourpreclinical and clinical development activities. We do not allocate employeecosts, costs associated with our platform technology or facility expenses,including depreciation or other indirect costs, to specific product developmentprograms because these costs are deployed across multiple product developmentprograms and, as such, are not separately classified.

Should we resume development of our product candidates, the successfuldevelopment and commercialization is highly uncertain. This is due to thenumerous risks and uncertainties, including the following:

successful completion of preclinical studies and clinical trials;

--------------------------------------------------------------------------------

Table of Contents

receipt and related terms of marketing approvals from applicable regulatoryauthorities;

raising additional funds necessary to complete clinical development of andcommercialize our product candidates;

obtaining and maintaining patent, trade secret and other intellectual propertyprotection and regulatory exclusivity for our product candidates;

making arrangements with third-party manufacturers, or establishingmanufacturing capabilities, for both clinical and commercial supplies of ourproduct candidates;

developing and implementing marketing and reimbursement strategies;

establishing sales, marketing and distribution capabilities and launchingcommercial sales of our products, if and when approved, whether alone or incollaboration with others;

acceptance of our products, if and when approved, by patients, the medicalcommunity and third-party payors;

effectively competing with other therapies;

obtaining and maintaining third-party coverage and adequate reimbursement;

protecting and enforcing our rights in our intellectual property portfolio;

maintaining a continued acceptable safety profile of the products followingapproval; and

the continuing impact of the COVID-19 pandemic on our industry, the healthcaresystem, and our current and future operations.

A change in the outcome of any of these variables with respect to thedevelopment of any of our product candidates would significantly change thecosts and timing associated with the development of that product candidate. Wemay never succeed in obtaining regulatory approval for any of our productcandidates.

Research and development activities have historically been central to ourbusiness model. Product candidates in later stages of clinical developmentgenerally have higher development costs than those in earlier stages of clinicaldevelopment, primarily due to the increased size and duration of later-stageclinical trials. We expect our research and development expenses to decrease inthe near future as we halted the development of our product candidates while weexplore strategic alternatives. Should we resume development of our productcandidates, we expect research and development costs to increase significantlyfor the foreseeable future as our product candidate development programsprogress.

Inflation generally affected us by increasing our cost of labor and clinicaltrial costs. While we do not believe that inflation had a material effect on ourfinancial condition and results of operations during the periods presented, itmay result in increased costs in the foreseeable future.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and relatedcosts, and stock-based compensation, for personnel in executive, finance andadministrative functions. General and administrative expenses also includedirect and allocated facility-related costs and insurance costs, as well asprofessional fees for legal, patent, consulting, pre-commercialization,accounting and audit services. We expect our general and administrative expensesto decrease in the near future due to recent workforce reductions. We do expectto incur significant costs, however, related to our exploration of strategicalternatives, including legal, accounting and advisory expenses and otherrelated charges.

Interest and Other Income, Net

Interest and other income, net, consists of interest income and miscellaneousincome and expense unrelated to our core operations.

Income Taxes

Since our inception, we have not recorded any U.S. federal or state income taxbenefits for the net losses we have incurred in each year or for our earnedresearch and orphan drug tax credits, due to our uncertainty of realizing abenefit from those items. As of December 31, 2022, we had net operating losscarryforwards for federal income tax purposes of $272.9 million, of which $17.5million begin to expire in 2035 and $255.4 million can be carried forwardindefinitely. As of December 31, 2022, we had net operating loss carryforwardsfor state income tax purposes of $272.6 million which begin to expire in 2035.As of December 31, 2022,

--------------------------------------------------------------------------------

Table of Contents

we also had available research and orphan drug tax credit carryforwards forfederal and state income tax purposes of $12.9 million and $3.4 million,respectively, which begin to expire in 2035 and 2030, respectively.

Critical Accounting Policies and Significant Judgments and Estimates

Excerpt from:
MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

How ice hockey helped me to explain how unborn babies’ brains are … – Nature.com

Jean Mary Zarate: 00:04

Hello and welcome to Tales From the Synapse, a podcast brought to you by Nature Careers in partnership with Nature Neuroscience. Im Jean Mary Zarate, the senior editor at the journal Nature Neuroscience. And in this series, we speak to brain scientists all over the world about their life, their research, their collaborations, and the impact of their work. In episode six, we meet a researcher and author who was fascinated by the evolution of our brains and how they develop in the womb.

William Harris: 00:39

Hi, my name is William Harris, people generally call me Bill. I'm a professor emeritus at Cambridge University. Im a developmental neurobiologist, and Im the author of Zero to Birth, How the Human Brain is Built.

A developmental neurobiologist is basically someone who studies how brains develop. Its usually done in the laboratory. Its a field at the intersection of developmental biology and neuroscience.

Its carried out usually at the level of experimental animals and cells in petri dishes and things like that, rather than on human embryos.

So myself, you know I worked on fly embryos, I worked on salamander embryos, frog embryos, fish embryos. There are tons of fascinating questions about how the brain is made.

I myself got interested in it when I was a graduate student, and I was studying some mutant fruit flies. And these mutant fruit flies, they didn't see the world properly, they made visual errors. So lots of people had isolated, weird mutant flies that didn't see properly.

And when we traced the genes that were defective, mutated in those animals, we usually found that they operated at some point in the development of the visual system.

So that, you know, all these genes work to build the brain. And thats what really got me interested in it. And from that point, I just got more and more interested in how this most complicated organ develops.

And my main questions were, like, you know, wiring up, how does it get wired up? Thats what I spent most of my career doing.

I am a Canadian. I grew up in Canada, and played a lot of ice hockey. That's why there's a lot of ice hockey references in the book, analogies or metaphors in the book.

At the age when I went to university, I went to University of California at Berkeley. I was a graduate student at Caltech. My PhD supervisor was a famous guy named Seymour Benzer. And he worked on behavioural mutants of flies. I did postdoctoral work at Harvard Medical School, in the laboratories of David Hubel and Torsten Weisel, who studied the visual cortex of mammals, and how that developed.

And then I had my own career starting at the University of California, San Diego, in the biology department. And about 25 years ago, I moved to the University of Cambridge, where Ive been since.

I wrote the book because I wanted to do something useful with the perspective I had from 40 years of research and teaching of developmental neurobiology, teaching to university students.

I thought I could offer a glimpse into the field for people who wondered about such things, and have never, ever studied the subject.

I found it really difficult to make such a complicated scientific pursuit fascinating. But I tried to instill in the book some of the stories of the discoveries that have been made.

You know, how exactly were these discoveries made? And I added some colour, because I think people like to know this by trying to tie these discoveries to medical progress in neurology and psychiatry and psychology. Because so many of the things that go wrong during brain development lead to neurological or psychological syndromes.

William Harris: 05:14

Well, human brains are really different from those of every other species of animal. In fact, the brains of every species of animal are different from each other because theyve been tuned through millions of years of evolution to their particular lifestyle.

For example, an insects brain is geared to an insects world. And a human brain is geared to human affairs. But what we found out is that the instructions for making a human brain are written in the human genome, so it's largely genetic.

If you transferred a little bit of mouse embryonic brain tissue into a culture system and a human, then a brain into a culture system, theyd make, you know, a little bit of mouse brain or a little bit of human brain. Theyre genetically instructed to do that.

But what way, what way are the brains different? For example, our brains are about 10 times larger than expected for an animal of our size.

Human brains are about four times as large as chimpanzee brains, even though we weigh about the same as they do.

The architecture of human brains is different and human-specific. And the best example is the cerebral cortex, the covering of the brain where higher functions are. You know, in humans its 75% of the mass of our brain is cerebral cortex. Whereas in others, in monkeys, its only about 50%. And in most mammals, its, you know, 20% to 30%.

So its really taken over the dominant role in humans. So certain areas have enlarged, in comparison to other animals, and certain areas have not enlarged, may have shrunk.

So another key difference is the way brains develop. Just one of them, for example, is the fact that humans are born immature. Because their brains are getting bigger and bigger, they, you know, there, it seems that they constrict. Well, theres a squeezed point in evolution where, you know, in the embryo, you couldnt get an animal with a bigger brain and deliver it safely.

So, humans are born with a growing brain, and its gonna get bigger, but its as big as a mother can manage at that time. But it means that the brain is still immature when the human is born, compared to when a monkey is born. And it takes a longer time. And then it matures for a longer time postnatally too. So they spend a lot more time, humans, spend a lot more time than our closest relatives in, in learning about the world outside the womb, and that having an effect on the maturation of the brain.

We call the brain this collection of neurons thats in the head region. There are certain really circular symmetric animals like jellyfish, and they dont really have a front and a back.

And they dont have what we call a brain. They do have a nervous system, and neurons that connect to each other. But we call that a nerve net, because there isnt one centralized group where most of the neurons are.

So in evolutionary time, when bilaterally symmetric animals evolved 500-600 million years ago, and started to move in a forward direction, (you know, there was a front and a back end), it made sense to collect things at the front end that the animal was going to engage in first with the world.

So sensory apparatus, move there, smell, taste, vision, and the capacity to process the information that comes in through those senses was handled by a growing collection of neurons, which we ended up calling the brain.

If you wanted to break it down, what happens in what trimester, you could kind of think of it like this....

You start as a fertilized egg, and this egg divides and one cell becomes two, two four, four eight, eight 16 and so on. You get this ball of cells. Now, every one of those cells has the potential to make a whole human being, theyve got the genetic instructions to do everything to make a brain.

But at some point in early development, only about three weeks post-fertilization, some of the cells, some of those cells become committed to make the brain. They become the Adams and Eves, if you will, of the brain.

And they arrange themselves into groups that are the founders of different regions of the brain. There are hundreds of different regions of the brain. But these are the neural stem cells, theyre still dividing, theyre proliferating.

And theyre going to make a brain of the right size and proportions. Theyre going to make a brain with 100 billion neurons by birth.

William Harris: 11:08

Then in the second trimester, growth slows down a little bit, and some of the first neurons are generated from the neural stem cells. And connections start to be built between these first neurons. So for example, in the second trimester, you can already see some movements in the human embryo. And thats because muscle cells have connected.

Well, neurons in the spinal cord have connected with muscle cells. And neurons in the brain have connected with those motor neurons. So babies begin to kick their whole leg, move in slightly coordinated ways, bring their hands to their mouths, things like that.

You can see that connectivity is happening in the brain. I likened it to how a team is formed, and I give ice hockey analogies in the book, because thats my, that was a sport I had played and still coach.

So a coach will have tryouts and select the best players for different positions. The brain does the same thing. Maybe two neurons try out for every position, one makes it thats a little bit better at communicating, and the other one doesnt, and the one that doesnt has to commit suicide. So they go through a process called, in the business, apoptosis, where they break their own cells apart. But the survivors, once they survived, they have to last your whole life.

William Harris: 12:49

And then, in the last trimester, these neuron production grinds to a halt. The wiring up process is still going on. And this period of competition between neurons for survival, and then synaptic territory, that continues. And the neurons have to connect with each other in really precise ways and get fine tuned.

And this is still happening in the embryo, but it means that, you know, that when youre older, for example, and youre hungry, youve got neurons in your hypothalamus that will sense hunger, you know, sense the nutrition level in your brain, and neurons in your retina that can see a visual image and, you know, maybe its, this is kind of the example I give in the book, maybe its an English muffin, a picture of an English muffin that you can interpret, you learn to interpret.

And then you learn to, you know, the olfactory circuit in your nose has learned to interpret the smells received as melting butter on a freshly toasted muffin.

And then the neurons in your frontal cortex organize these pieces of information and integrate them, and send signals to the motor cortex. And the motor cortex then sends signals down the spinal cord to your motor neurons that organize a sequence of actions so that you can reach out and grab this muffin and bring it to your mouth and take a tasty bite. So a lot of that circuitry has been refined during the third trimester. Not all of it, but a lot of it.

We dont even really know how many types of neurons there are in the brain, but 1000s at least. Given that its the most complicated organ that we have, its not surprising that there are lots of different cell types. Its even been shown by recent science that every neuron in the brain has a distinct molecular identity from every other neuron in the brain. And it has a particular job.

Obvious for people are things like the rods and cones of our eyes, but the red, green, and blue-perceiving photoreceptors in the retina. So thats the three types of photoreceptors, the cone photoreceptors. And theres one type of rod cell. And then those four different photoreceptor types send their information to about 20 different next-order cell types. And they send their information to another 40 different next-order cell types, and so forth.

So by the time the image leaves the retina, the neural signal leaves the retina, its been seen by hundreds of different types of neurons, each doing a different kind of processing job.

There are lots of different types of neurons, some are numerous and tiny, and some are large, and few.

And one of the ones thats large and fewer are the dopaminergic neurons in the forebrain, whose degeneration is linked to Parkinsons disease. They're dopamine-secreting neurons. And they have exons that spread out across the cortex and many other areas of the brain. And they tone the brain, allowing people to initiate movements and things like that.

When they degenerate, then you develop Parkinsons disease. So different neurons, you can find out their function because when they when theyre gone, it reveals a defect, colour blindness, Parkinsons disease, and many other syndromes and neurological disorders are caused by defects in the formation of particular types of neurons.

William Harris: 17:03

Well, although the nervous system has started to fire up, its active before birth. And these prenatal activity patterns work, kind of like, test TV test patterns, if you remember those.

And theyre important to start to begin to tune brain function. But its only after a baby has been born that the outside world can have and does have such an influence on the activity patterns of the brain.

And so the outside world begins to fine tune the circuitry of the brain. The baby learns what its mother's face looks like, and many other things, the smell of coffee, or a muffin.

The babys brain, we say its over-wired. That means too many connections, there are too many connections. But its also under-connected because the connections arent very strong at the beginning.

And these connections need to continue to mature in the outside world. Synapses do continue to change to some extent throughout life, which is how people learn new things and forget other things.

William Harris: 18:28

Its interesting to think about the brain and the way the brain develops in two basic stages. One is building everything. And then the next stage is refining things. During the building phase youre constructing, adding more and more and more.

And during the refining phase, youre getting rid of stuff. For example, you might build a building, you might have scaffolding, and you put it up, and then you have to take it down at the end.

You may have brought in way too many bricks to build the building and have to discard some of those bricks at the end because they werent fit for purpose.

Well, the brain has a construction phase, and a destruction phase, or a decluttering phase. So first, you know, by the time a baby is born, it has more neurons than it will ever have in the rest of its life.

Neurons are dying at a faster rate than they are being born in a baby. In fact, neuronal birth has ground to a halt pretty much at the time of birth. But neurons are dying in vast numbers.

An adult human only has about half the neurons that it produced during its development. But once the brain has gone through this initial period of cell death, when its refined, got rid of the neurons that don't work so well, those neurons have to survive the rest of a lifetime because they dont divide anymore. And we dont have any neural stem cells left.

But what the survivors do is they continue to work against and with each other to gain or lose synaptic territory, and synaptic influence. And that continues on throughout life.

So, you know, a neuron might have a branch that goes to another area, and that branch might get pruned away, because someone else has taken over that territory. Those kinds of things happen, largely in childhood, but also, to a lesser extent, in an adult human.

William Harris: 20:45

My career, and particularly writing this book, has influenced the way I look at certain things, particularly my grandchildren, and one of my grandchildren features in the book a couple times.

One is about, you know, how people learn to be afraid of spiders, and whether epigenetics is involved or not.

And another is learning to speak. So babies are born with the potential to understand language. And their brains are already wired, so that they will be capable of getting it, but they cant speak yet.

So how does that happen? We talk about that in the book. But it wasnt my research so much, but it was really writing this book that changed my outlook, because I started to think about those things from a human perspective, instead of a fish brain perspective.

When I was researching, I was thinking about fish brains and fish retinas, writing a book starting to think more about human brains.

And I learned a lot about the connections between evolution and development in the brain. So how animal brains are like ours, and how theyre different from ours.

And the way its changed my outlook has, certainly, its increased my respect for what animals brains are and what animals are up, when I look at an animal.

And its also increased my respect for humans, because each one of us is born with a very unique brain. The developmental mechanisms that are used to make a brain ensures that your brain is going to be very different than my brain, its gonna be very different even if you had an identical twin brother, or sister that, you know, was grown in the same environment and had the same genes.

Theres a little bit of randomness thats thrown in. Probably our brains are the most unique things about us. We have unique faces, but our brains are even more unique. Just you cant see them.

23:06: Jean Mary Zarate

Now thats it for this episode of Tales From the Synapse. I'm Jean Mary Zarate, a senior editor at Nature Neuroscience. The producer was Don Byrne. Thanks again to Professor William Harris, and thank you for listening.

Here is the original post:
How ice hockey helped me to explain how unborn babies' brains are ... - Nature.com

Aptose Reports Results for the Fourth Quarter and Full Year 2022 – GlobeNewswire

APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax

RAS Mutated AML Clinically Sensitive to Tuspetinib

Continuous Dosing of G3 Formulation of Luxeptinib Ongoing

Conference Call and Webcast at 5:00 pm ET Today

SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose or the Company) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

The net loss for the quarter ended December 31, 2022, was $10.0 million ($0.11 per share) compared with $24.3 million ($0.27 per share) for the quarter ended December 31, 2021. The net loss for the year ended December 31, 2022, was $41.8 million ($0.45 per share) compared with $65.4 million ($0.73 per share) for the year ended December 31, 2021. Total cash and cash equivalents and investments as of December 31, 2022, were $47.0 million. Based on current operations, Aptose expects that cash on hand and available capital provide the Company with sufficient resources to fund planned Company operations including research and development into the first quarter of 2024.

To expand on the clinically significant response data observed across a broad population of acute myeloid leukemia (AML) patients during the dose escalation and exploration phase of our trial, we rapidly transitioned to our APTIVATE Phase 1/2 expansion trial with tuspetinib. APTIVATE already is running smoothly with several AML patients being treated in the monotherapy arm, and patient enrollment now is underway in the doublet combination treatment arm with tuspetinib and venetoclax (TUS/VEN). And we are eager to bring additional data to you throughout the year, said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. We anticipate enrolling up to 100 patients in the APTIVATE study, from which we expect to demonstrate single agent activity that can guide multiple paths for potential accelerated approval in patients with adverse mutations, and to demonstrate activity in doublet and then triplet combination therapies, which we believe represent the future directions of AML treatment. Tuspetinibs single agent activity targets more AML populations than SYK inhibitors, IRAK4 inhibitors, or menin inhibitors, and, its distinctly favorable safety profile also lends itself to an ideal combination treatment to potentially treat larger AML patient populations in earlier lines of therapy.

Key Corporate Highlights

Tuspetinib is designed to simultaneously target SYK, JAK1/2, FLT3, RSK and other kinases operative in AML. As a monotherapy treatment during dose escalation and exploration in our Phase 1/2 trial, tuspetinib safely delivered multiple complete remissions and clinical responses across four dose levels (40mg, 80mg, 120mg, and 160mg) in AML patients that previously had been failed by chemotherapy, BCL2 inhibitors, hypomethylating agents, FLT3 inhibitors, and hematopoietic stem cell transplants. Data presented in December at the 2022 American Society of Hematology (ASH) annual meeting by lead investigator Naval G. Daver, M.D., Associate Professor in the Department of Leukemia at MD Anderson Cancer Center, showed tuspetinib delivers single agent responses without prolonged myelosuppression or life-threatening toxicities in these very ill and heavily pretreated R/R AML patients. Responses were observed in a broad range of mutationally-defined populations, including those with mutated forms of NPM1, MLL, TP53, DNMT3A, RUNX1, wild-type FLT3, ITD or TKD mutated FLT3, various splicing factors, and other genes. Unexpectedly, we observed a 29% CR/CRh response rate with tuspetinib monotherapy in patients having mutations in the RAS gene or other genes in the RAS pathway. Responses in RAS-mutated patients are important because the RAS pathway is often mutated in response to therapy by other agents as the AML cells mutate toward resistance to those other agents.

With dose escalation and exploration successfully completed, we now are focusing on execution of the APTIVATE Phase 1/2 expansion trial. While we plan to report data throughout the year, we also will plan an incremental update from APTIVATE around the European Hematology Association (EHA) conference in June, a more complete dataset at the European School of Haematology (ESH) meeting in October, and even more data, including from the TUS/VEN combination cohort, during the ASH meeting in December.

Separately, a small number of B-cell patients are still receiving the original G1 formulation of luxeptinib at the 900 mg dose level. During ASH in December, we announced that a CR was achieved with a diffuse large B-cell lymphoma patient at the 900 mg dose level of the original G1 formulation, and we had previously reported an MRD-negative CR with a R/R AML patient receiving 450 mg BID of the original G1 formulation. Together, these findings demonstrate activity of luxeptinib in lymphoid malignancies and AML.

Research on luxeptinib continues, and a non-clinical paper was published earlier this month in PLOS One, a highly respected online scientific publication. Titled, Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma, the paper helps to elucidate the mechanism by which Lux suppresses the B-cell receptor pathway in a manner distinct from the BTK inhibitor ibrutinib. Lux was more effective than ibrutinib at reducing both steady state and anti-IgM-induced phosphorylation of the LYN and SYK kinases upstream of BTK where ibrutinib has little or no effect, suggesting Lux can play a role in B-cell malignancies and inflammatory diseases distinct from ibrutinib and other BTK inhibitors.

RESULTS OF OPERATIONS

A summary of the results of operations for the years ended December 31, 2022 and 2021 is presented below:

Net loss of $41.8 million for the year ended December 31, 2022 decreased by approximately $23.5 million as compared with $65.4 million for the year ended December 31, 2021, primarily as of a result of a reduction in research and development program costs and personnel expenses of $5.4 million, the $12.5 million in license fees paid to Hanmi in 2021 for development rights of tuspetinib, and a $5.0 million decrease in general and administrative costs.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred related to the research and development of our product candidates. Costs include the following:

We have ongoing clinical trials for our product candidates tuspetinib and luxeptinib. Tuspetinib was licensed into Aptose in November 2021 and we assumed sponsorship, and the related costs, of the tuspetinib study effective January 1, 2022. In December 2021, we discontinued the APTO-253 program and are exploring strategic alternatives for this compound.

We expect our research and development expenses to be higher as compared to 2022 for the foreseeable future as we continue to advance tuspetinib into larger clinical trials.

The research and development (R&D) expenses for the years ended December 31, 2022 and 2021 were as follows:

R&D expenses decreased by $17.9 million to $28.1 million for the year ended December 31, 2022 as compared with $46.0 million for the comparative period in 2021. Changes to the components of our R&D expenses presented in the table above are primarily as a result of the following activities:

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and travel, including stock-based compensation for our executive, finance, business development, human resource, and support functions. Other general and administrative expenses and professional fees for auditing, and legal services, investor relations and other consultants, insurance and facility related expenses.

We expect that our general and administrative expenses will increase for the foreseeable future as we incur additional costs associated with being a publicly traded company and to support our expanding pipeline of activities. We also expect our intellectual property related legal expenses to increase as our intellectual property portfolio expands.

The general and administrative expenses for the years ended December 31, 2022 and 2021 are as follows:

COVID-19 did not have a significant impact on our results of operations for the years ended December 31, 2022 and 2021. We have not experienced and do not foresee material delays to the enrollment of patients or timelines for the tuspetinib Phase 1/2 trial or the luxeptinib Phase 1a/b trials due to the variety of clinical sites that we have actively recruited for these trials. As of the date of this press release, we have not experienced material delays in the manufacturing of tuspetinib or luxeptinib related to COVID-19. Should our manufacturers be required to shut down their facilities due to COVID-19 for an extended period of time, our trials may be negatively impacted.

Conference Call & Webcast:

(https://register.vevent.com/register/BI9394078d0ea14714aca591ffe06992f1)

*Analysts interested in participating in the question-and-answer session will pre-register for the event from the participant registration link above to receive the dial-in numbers and a personal PIN, which are required to access the conference call. They also will have the option to take advantage of a Call Me button and the system will automatically dial out to connect to the Q&A session.

The audio webcast also can be accessed through a link on the Investor Relations section of Aptoses website here. A replay of the webcast will be available on the companys website for 30 days.

The press release, the financial statements and the managements discussion and analysis for the quarter and year ended December 31, 2022 will be available on SEDAR at http://www.sedar.com and EDGAR at http://www.sec.gov/edgar.shtml.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase 1/2 expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit http://www.aptose.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements regarding the expected cash runway of the Company, the clinical development plans, the clinical potential, anti-cancer activity, therapeutic potential and applications and safety profile of tuspetinib and luxeptinib, the APTIVATE clinical trial, patient enrollment, potential accelerated approval, the luxeptinib Phase 1 a/b clinical trials and the upcoming milestones of such trials, the development and clinical potential of a new formulation (G3) for luxeptinib, expected variations in expenses, upcoming updates regarding the clinical trials, the exploration of strategic alternatives for the APTO-253 program, the expected impact of COVID-19 on results and operations and statements relating to the Companys plans, objectives, expectations and intentions and other statements including words such as continue, expect, intend, will, hope should, would, may, potential and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; the potential impact of the COVID-19 pandemic and other risks detailed from time-to-time in our ongoing current reports, quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

For further information, please contact:

The rest is here:
Aptose Reports Results for the Fourth Quarter and Full Year 2022 - GlobeNewswire

Why Does a Leukemic Mutation Not Always Lead to the Disease? – Technology Networks

Register for FREE to listen to this article

Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Why do some people with a genetic mutation associated with leukemia remain healthy, while others with the same mutation develop the blood cancer? In a new study published inBlood, scientists from the USC Stem Cell laboratory of Rong Lu discovered a mechanism that linked a leukemic mutation to varying potentials for disease development a discovery which could eventually lead to a way to identify patients with the mutation who are most at risk.

To explore this paradox, first author Charles Bramlett and his colleagues labeled and tracked individual blood stem cells in mice with a mutation in a gene called TET2, which is prevalent in patients with myeloid leukemia. The scientists found that a subset of blood stem cells and their progenyknown as clonesmade an outsized contribution to the overall population of blood and immune cells. The over-contributing clones tended to produce a lot of myeloid cells including immune cells called granulocytes, which may potentially lead to myeloid leukemia.

There were also notable differences in the gene activity of the over-contributing clones, compared to the rest of the clones. The over-contributing clones showed reduced activity in several genes known to suppress the development of leukemia and other cancers. They also showed reduced activity in genes that are involved in RNA splicing, the process of removing non-coding sequences from the RNA that carries messages from the DNA to the cells protein-making machinery.

One of these RNA splicing genes, Rbm25, showed a particularly dramatic reduction in its activity in the over-contributing clones. To explore the effect of Rbm25, the scientists used CRISPR/Cas9 gene editing to manipulate the activity of Rbm25 in cells with TET2 mutations. They found that increasing Rbm25 activity slowed the cells proliferation. In contrast, reducing Rbm25 activity made the cells multiply more quickly, and also caused changes in RNA splicing of the geneBcl2l1,which regulates programmed cell death, also known as apoptosis. The natural process of apoptosis is critical for ridding the body of aberrant cells, such as pre-cancerous cells that multiply too aggressively and accumulate dangerous mutations that can lead to disease.

Subscribe to Technology Networks daily newsletter, delivering breaking science news straight to your inbox every day.

In accordance with these new discoveries in mice, Rbm25 activity is also negatively correlated with white blood cell counts that mark poor survival in human patients with myeloid leukemia.

Our study suggests that a leukemia-associated genetic mutation could trigger different amounts of myeloid cell production, which may be modulated by other risk factors such as RNA splicing regulators, said Lu, an associate professor of stem cell biology and regenerative medicine, biomedical engineering, medicine, and gerontology at USC, and a Leukemia & Lymphoma Society Scholar. These findings could be used to better stratify which patients are at the highest risk, and also present intriguing possibilities for developing future therapies that target aberrant RNA splicing in preleukemia phases.

Reference:Bramlett C, Eerdeng J, Jiang D, et al. RNA splicing factor Rbm25 underlies heterogeneous preleukemic clonal expansion in mice. Blood. 2023:blood.2023019620. doi:10.1182/blood.2023019620

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Originally posted here:
Why Does a Leukemic Mutation Not Always Lead to the Disease? - Technology Networks

Link named oncology division director Washington University … – Washington University School of Medicine in St. Louis

Visit the News Hub

Leukemia specialist is leader in research, patient care

Daniel Link, MD, has been named director of the Division of Oncology at Washington University School of Medicine in St. Louis.

Daniel C. Link, MD, a highly regarded physician-scientist who treats patients with leukemia and also conducts innovative research aimed at developing better treatments for the blood cancer, has been named director of the Division of Oncology in the Department of Medicine at Washington University School of Medicine in St. Louis.

In addition, Link, who also is the Alan A. and Edith L. Wolff Distinguished Professor of Medicine, is deputy director of Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine.

Link will continue the work of John F. DiPersio, MD, PhD, the Virginia E. and Sam J. Golman Professor of Medicine, who has led the Division of Oncology since 1997 and served as Sitemans first deputy director. DiPersio, a world-renowned physician-scientist specializing in the treatment of leukemia with immunotherapies and stem cell transplants, is stepping down from these leadership roles to return to full-time patient care and research to improve strategies for stem cell transplantation, treat graft-versus-host disease and develop novel types of CAR-T cell therapies for blood cancers.

Dr. Link is exceptionally qualified to take on this new role, said Victoria J. Fraser, MD, the Adolphus Busch Professor of Medicine and head of the Department of Medicine. He is an outstanding physician-scientist with tremendous leadership skills and was chosen for this position after an extensive national search. He is a national leader in leukemia research and is an exceptional mentor for fellows, postdoctoral scholars and junior faculty, many of whom have gone on to leadership positions in the field. I also want to recognize and extend my sincere gratitude to Dr. DiPersio for his exceptional leadership as the inaugural oncology division director for 25 years and his outstanding contributions as the deputy director of Siteman Cancer Center.

Link, also a professor of pathology & immunology, is a world leader in understanding hematopoiesis, the process by which different types of blood cells are formed. He has made key advances in the field of stem cell transplantation for the treatment of blood cancers. As the principal investigator of a prestigious Specialized Program of Research Excellence (SPORE) in Leukemia, an estimated $23 million grant, Link leads efforts aimed at boosting translational research and moving promising investigational treatments developed at Washington University into clinical trials. Such grants, funded by the National Institutes of Health (NIH), are highly competitive and a cornerstone of the National Cancer Institutes (NCIs) efforts to support collaborative, interdisciplinary translational cancer research. Link also has served as co-leader of the Hematopoiesis Development and Malignancy Program at Siteman Cancer Center since 2005.

Over the past 10 years, Link has helped to develop the hematopoietic malignancy program at Washington University into one of the top such programs in the country. Link has served as a mentor to 46 pre- or postdoctoral trainees, many of whom have established independent laboratories at Washington University and elsewhere. His commitment to mentoring and developing the next generation of scientists has been recognized with the universitys Outstanding Faculty Mentor Award and the Distinguished Faculty Award for Graduate Student Teaching. In 2015, he received the School of Medicine Alumni Faculty Achievement Award.

Link earned his bachelors degree from the University of Wisconsin-Milwaukee and his medical degree from the University of Wisconsin-Madison. He completed his residency in medicine at what was then Barnes Hospital and a fellowship in hematology-oncology at Washington University School of Medicine. He joined the faculty in 1993 and has remained at the School of Medicine for his entire career.

About Washington University School of Medicine

WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,800 faculty. Its National Institutes of Health (NIH) research funding portfolio is the third largest among U.S. medical schools, has grown 52% in the last six years, and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,800 faculty physicians practicing at 65 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Childrens hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

Follow this link:
Link named oncology division director Washington University ... - Washington University School of Medicine in St. Louis

From mutation to arrhythmia: Desmosomal protein breakdown as an … – Science Daily

Mutations in genes that form the desmosome are the most common cause of the cardiac disease arrhythmogenic cardiomyopathy (ACM), which affects one in 2000 to 5000 people worldwide. Researchers from the group of Eva van Rooij now discovered how a mutation in the desmosomal gene plakophilin-2 leads to ACM. They found that the structural and functional changes in ACM hearts caused by a plakophilin-2 mutation are the result of increased desmosomal protein degradation. The results of this study, published in Science Translational Medicine on March 22nd 2023, further our understanding of ACM and could contribute to the development of new therapies for this disease.

ACM is a progressive and inheritable cardiac disease for which currently no treatments exist to halt its progression. Although patients initially do not experience any symptoms, they are at a higher risk of arrhythmias and resulting sudden cardiac arrest. As the disease progresses, patches of fibrotic and fat tissue form in the heart which can lead to heart failure. At this stage, patients require a heart transplantation as treatment.

Plakophilin-2

Over 50% of all ACM cases are caused by a mutation in one of the desmosomal genes, which together form complex protein structures known as desmosomes. Desmosomes form "bridges" between individual heart muscle cells, allowing the cells to contract in a coordinated manner. Most of the desmosomal mutations that cause ACM occur in a gene called plakophilin-2. Nevertheless, very little is known on how mutations in this gene lead to the disease. To change this, the Van Rooij lab first studied human heart samples from ACM patients carrying mutations in the plakophilin-2 gene. "We saw lower levels of all desmosomal proteins and disorganized desmosomal proteins in fibrotic areas of the ACM hearts," says Jenny (Hoyee) Tsui, first author on the paper. Tsui: "In addition, cultured 3D heart muscle tissue originating from a patient with a plakophilin-2 mutation, was unable to continue beating at higher pacing rates, which resembles arrhythmias seen in the clinic."

ACM in mice

The researchers then used a genetic tool called CRISPR/Cas9 to introduce the human plakophilin-2 mutation in mice to mimic ACM. This allowed them to study progression of the disease in more detail. They observed that old ACM mice carrying this mutation had lower levels of desmosomal proteins and heart relaxation issues, similar to ACM patients. Strikingly, the researchers discovered that the mutation lowered levels of desmosomal proteins even in young, healthy mice of which the heart contracted normally. From this they concluded that a loss of desmosomal proteins could underlie the onset of ACM caused by a plakophilin-2 mutation.

Protein degradation

The researchers then moved on to explain the loss of desmosomal proteins. For this they studied both RNA and protein levels in their ACM mice. "The levels of desmosomal proteins were lower in our ACM mice compared to healthy control mice. However, the RNA levels of these genes were unchanged. We discovered that these surprising findings are the result of increased protein degradation in ACM hearts," explains Sebastiaan van Kampen, co-first author of the paper. Tsui adds: "When we treated our ACM mice with a drug that prevents protein degradation, the levels of desmosomal proteins were restored. More importantly, the restored levels of desmosomal proteins improved calcium handling of heart muscle cells, which is vital for their normal function."

Towards new therapies

The results of this study, published in Science Translational Medicine, raise new insights into ACM development and indicate that protein degradation could be an interesting target for future therapies. "Protein degradation occurs in every cell of our body and is crucial for the function of these cells. To overcome side-effects of future therapies we will need to develop drugs that prevent degradation of desmosomal proteins in heart muscle cells specifically," explains Eva van Rooij, group leader at the Hubrecht Institute and last author of the study. More research is thus needed to realize this. In the future, these new specific drugs could potentially be used to halt the onset and prevent progression of ACM.

Link:
From mutation to arrhythmia: Desmosomal protein breakdown as an ... - Science Daily